HIV/AIDS
Researchers from the United States and France describe findings in HIV/AIDS studies
Published in AIDS Weekly, June 19th, 2006
Study 1: Clinical markers and tolerability are similar among HIV-infected patients given protease inhibitor or non-nucleoside reverse-transcriptase inhibitor-based regimens during early infection.
"Treatment of acute human immunodeficiency virus type 1 (HIV-1) infection may have unique immunologic, virological, and clinical benefits. However, the timing of treatment, optimal starting regimens, and expected response to therapy have not been defined," scientists in the United States report.
According to S. Kassutto and colleagues at Massachusetts...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2006-06-19)
More Articles from AIDS Weekly
- HIV/AIDS Drug Development
Phosphorothioate oligonucleotides inhibit HIV-1 fusion by blocking gp41 core formation - HIV/AIDS HAART
Genotype-guided HAART in early infection may be effective against drug-resistant HIV-1 - HIV/AIDS HAART
Lopinavir and ritonavir have limited penetration in the male genital tract - HIV/AIDS Pneumonia
HIV+ children with severe pneumonia fail treatment more often than uninfected children - HIV/AIDS Vaginal Microbicide
Synthetic-2 RANTES effective and nontoxic as a CCR5-targeted vaginal microbicide - Anemia
Iron supplement does not increase hemoglobin and ferritin levels in malaria-prevalent area - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
